TABLE 1.
Sequence alignment in the discriminatory region of the amplified matrix gene from 37 clinical isolates with atypical Tms using the Mayo FLU A assay
| Sequence source or patient no. | Mayo FLU A Tm (°C) | Statea | Sequence of discriminatory region of M gened |
||
|---|---|---|---|---|---|
| Fluorescein probe | CTb | Red 640 probe | |||
| WHO sequence | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAACACAGATCTTGAGGC | ||
| 1 | 55.5 | MI | CGAAATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAACACAGATCTTGAGGC |
| 2 | 47.8 | PA | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATACAGATCTTGAGGC |
| 3c | 47.4 | PA | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATACAGATCTTGAGGC |
| 4c | 47.4 | PA | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATACAGATCTTGAGGC |
| 5c | 47.5 | PA | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATACAGATCTTGAGGC |
| 6c | 47.6 | PA | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATACAGATCTTGAGGC |
| 7 | 47.9 | PA | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATACAGATCTTGAGGC |
| 8 | 47.6 | PA | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATACAGATCTTGAGGC |
| 9c | 41.6 | OH | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATATAGATCTTGAGGC |
| 10 | 41.8 | OH | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATATAGATCTTGAGGC |
| 11c | 41.9 | OH | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATATAGATCTTGAGGC |
| 12 | 47.6 | OH | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATACAGATCTTGAGGC |
| 13 | 47.6 | OH | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATACAGATCTTGAGGC |
| 14 | 47.7 | OH | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATACAGATCTTGAGGC |
| 15 | 47.5 | OH | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATACAGATCTTGAGGC |
| 16 | 48.0 | OH | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATACAGATCTTGAGGC |
| 17 | 47.6 | OH | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATACAGATCTTGAGGC |
| 18 | 47.6 | OH | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATACAGATCTTGAGGC |
| 19 | 47.7 | OH | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATACAGATCTTGAGGC |
| 20 | 46.1 | OH | CGAGATCGCACAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAACACAGATCTTGAGGC |
| 21 | 45.6 | OH | CGAGATCGCACAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAACACAGATCTTGAGGC |
| 22 | 45.4 | OH | CGAGATCGCGCAGAGATTGGAAAGTGT | CT | TTGCAGGAAAGAACACAGATCTTGAGGC |
| 23 | 45.1 | MN | CGAGATCGCGCAGAGAATGGAAAGTGT | CT | TTGCAGGAAAGAACACAGATCTTGAGGC |
| 24 | 45.1 | MN | CGAGATCGCGCAGAGAATGGAAAGTGT | CT | TTGCAGGAAAGAACACAGATCTTGAGGC |
| 25 | 46.2 | MN | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAACACAGATCTTGAGGC |
| 26c | 47.4 | MN | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAACATAGATCTTGAGGC |
| 27c | 47.3 | MN | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAACATAGATCTTGAGGC |
| 28c | 48.1 | MN | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATACAGATCTTGAGGC |
| 29 | 45.3 | MA | CGAGATCGCGCAGAGGCTGGAAAGTGT | CT | TTGCAGGAAAGAACACAGATCTTGAGGC |
| 30 | 45.1 | MA | CGAGATCGCGCAGAGGCTGGAAAGTGT | CT | TTGCAGGAAAGAACACAGATCTTGAGGC |
| 31 | 45.5 | MA | CGAGATCGCGCAGAGGCTGGAAAGTGT | CT | TTGCAGGAAAGAACACAGATCTTGAGGC |
| 32 | 45.5 | MA | CGAGATCGCGCAGAGGCTGGAAAGTGT | CT | TTGCAGGAAAGAACACAGATCTTGAGGC |
| 33c | 45.7 | AZ | CGAGATCGCACAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAACACAGATCTTGAGGC |
| 34c | 46.0 | AZ | CGAGATCGCACAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAACACAGATCTTGAGGC |
| 35 | 46.0 | AZ | CGAGATCGCACAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAACACAGATCTTGAGGC |
| 36 | 47.3 | Kuwait | CGAGATCGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAATACAGATCTTGAGGC |
| 37 | 44.4 | NY | CGAGATTGCGCAGAGACTGGAAAGTGT | CT | TTGCAGGAAAGAACACAGATCTTGAGGC |
a
State where patient resided, specifically Ann Arbor, MI; Sewickley, PA; Beaver, PA; Cleveland, OH; Owatonna, MN; Racine, MN; Rochester, MN; Spring Valley, MN; Northampton, MA; Phoenix, AZ; Salusai, Kuwait; and Utica, NY.
b
CT is a two-base-pair sequence between the fluorescein probe and the red 640 probe.
c
Previously published sequences (3). One previously published sequence was not included in the final data due to inconsistent results.
d
All mutations are shown in bold.